"10.1371_journal.pone.0110183","plos one","2014-10-20T00:00:00Z","Antonio DiGiandomenico; Ruth Ann Veach; Jozef Zienkiewicz; Daniel J Moore; Lukasz S Wylezinski; Martha A Hutchens; Jacek Hawiger","Department of Microbiology and Immunology Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America; Immunotherapy Program at Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America; Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America; Department of Pediatrics, Ian Burr Division of Endocrinology and Diabetes, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America; Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America; Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America","Conceived and designed the experiments: AD RAV JZ JH. Performed the experiments: AD RAV JZ DJM LSW MAH. Analyzed the data: AD RAV JZ JH. Contributed to the writing of the manuscript: AD RAV JZ JH.","JH, RAV, and JZ are co-inventors of patents relating to cell-penetrating NTM peptides and their use for anti-inflammatory therapy. All rights are assigned to Vanderbilt University. JH is co-founder and shareholder of AGH Therapeutics, Inc. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials. The authors have no other financial conflicts of interest relating to the subject matter or materials discussed in this article. All work performed by AD was completed during his post-doctoral training at Vanderbilt University prior to and not related to his current employment at MedImmune.","2014","10","Antonio DiGiandomenico","ADG",7,TRUE,4,6,4,NA,TRUE,TRUE,FALSE,0,NA,FALSE
